Incyte (INCY)
NASDAQ:INCY
Want to see INCY full AI Analyst Report?
INCY Stock Chart & Stats
$97.82
$0.53(0.72%)
At close: 4:00 PM EST
$97.82
$0.53(0.72%)
Day’s Range― - ―
52-Week Range$66.74 - $112.29
Previous CloseN/A
Volume384.35K
Average Volume (3M)1.68M
Market Cap
$19.62B
Enterprise Value$16.35B
Total Cash (Recent Filing)$4.02B
Total Debt (Recent Filing)$33.83M
Price to Earnings (P/E)13.7
Beta0.46
Next Earnings
Aug 04, 2026EPS Estimate
1.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.30
Shares Outstanding199,782,150
10 Day Avg. Volume2,226,383
30 Day Avg. Volume1,676,986
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.73
Price to Sales (P/S)3.75
P/FCF Ratio14.23
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue3.05
Enterprise Value/Gross Profit3.30
Enterprise Value/Ebitda8.74
Forecast
1Y Price Target
$111.13Price Target Upside13.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
EPS Forecast (FY)7.53
Revenue Forecast (FY)$5.62B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage (debt-to-equity ~0.01) provides durable financial flexibility to fund late-stage trials, launches and M&A without refinancing stress. This reduces bankruptcy and liquidity risk and supports multi-quarter investments even if approvals are delayed.
Cash Generation & MarginsConsistently strong TTM operating and free cash flow with very high gross and operating margins gives Incyte sustained ability to self-fund R&D, commercialization and capital allocation. Robust cash generation underpins multi-year investment without reliance on frequent external financing.
Pipeline Diversification & Strategic M&AAdding VGA039 via Vega acquisition and multiple late-stage programs broadens hematology exposure and reduces single-product dependence. A first-in-class Phase 3 asset with regulatory designations materially strengthens long-term growth optionality and complements existing oncology/dermatology franchises.
Bears Say
Jakafi Revenue ConcentrationJakafi still drives a large portion of sales, leaving Incyte exposed if label, competitive, or reimbursement pressures emerge. Persistent concentration amplifies revenue volatility and makes multi-year growth contingent on successful XR conversion and new product launches to diversify the franchise.
Elevated R&D And Operating SpendSustained, high R&D and SG&A guidance reflects heavy investment across multiple late-stage programs. While strategic, this raises the structural risk of prolonged pressure on GAAP profitability and increases the need for continued strong cash generation or financing if clinical timelines slip.
Clinical Safety & Execution RiskA pneumonitis signal and administrative hold introduce regulatory scrutiny that can delay trials, raise development costs, or constrain labeling. Safety-related interruptions on an important oncology program can materially shift timelines and the commercial outlook over multiple quarters.
Incyte News
INCY FAQ
What was Incyte’s price range in the past 12 months?
Incyte lowest stock price was $66.74 and its highest was $112.29 in the past 12 months.
What is Incyte’s market cap?
Incyte’s market cap is $19.62B.
When is Incyte’s upcoming earnings report date?
Incyte’s upcoming earnings report date is Aug 04, 2026 which is in 46 days.
How were Incyte’s earnings last quarter?
Incyte released its earnings results on Apr 28, 2026. The company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.339 by $0.471.
Is Incyte overvalued?
According to Wall Street analysts Incyte’s price is currently Undervalued.
Does Incyte pay dividends?
Incyte does not currently pay dividends.
What is Incyte’s EPS estimate?
Incyte’s EPS estimate is 1.77.
How many shares outstanding does Incyte have?
Incyte has 199,782,150 shares outstanding.
What happened to Incyte’s price movement after its last earnings report?
Incyte reported an EPS of $1.81 in its last earnings report, beating expectations of $1.339. Following the earnings report the stock price went up 2.116%.
Which hedge fund is a major shareholder of Incyte?
Currently, no hedge funds are holding shares in INCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Incyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$111.13 (13.60% Upside)
$111.13 (13.60% Upside)
Blogger Sentiment
Bullish
INCY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.86%
12-Months-Change
Fundamentals
Return on Equity
29.31%
Trailing 12-Months
Asset Growth
27.65%
Trailing 12-Months
Company Description
Incyte
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
INCY Company Deck
INCY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and substantial pipeline/regulatory progress: double‑digit top‑line growth (Q1 revenue +21%, net sales +20%), outsized core ex‑Jakafi growth (+63% YoY), multiple late‑stage programs and regulatory acceptances (povorcitinib, 989 EOP meeting, 734 Phase III) and leadership hires to support launches. Offsetting risks include elevated R&D/operating spend, a small safety review and administrative hold related to pneumonitis in the 734 program, and continued revenue concentration in Jakafi. On balance the positives—robust revenue growth, core business acceleration, and clear late‑stage catalysts—outweigh the lowlights, though execution and safety monitoring remain important near‑term considerations.View all INCY earnings summariesINCY Revenue Breakdown
84.69% Product revenues, net
12.39% Product royalty revenues
2.92% Milestone and contract revenues
INCY Stock 12 Month Forecast
Average Price Target
$111.13
▲(13.60% Upside)
Technical Analysis
Ownership Overview
15.20% Insiders
23.18% Mutual Funds
18.20% Other Institutional Investors
15.16% Public Companies and Individual Investors